European biotechs urged to collaborate with Asian hubs for funding

💊 𝗘𝘂𝗿𝗼𝗽𝗲’𝘀 𝗯𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮 𝗶𝘀 𝗮𝘁 𝗮 𝗰𝗿𝗼𝘀𝘀𝗿𝗼𝗮𝗱𝘀 — 𝘢𝘯𝘥 𝘪𝘵’𝘴 𝘵𝘪𝘮𝘦 𝘵𝘰 𝘱𝘪𝘤𝘬 𝘢 𝘭𝘢𝘯𝘦. While the U.S. and China are turbo-charging biotech investment and speeding up approvals, Europe seems… stuck in a regulatory traffic jam🚦 Let’s face it: ❌ 𝙘𝙤𝙢𝙥𝙡𝙚𝙭 𝙧𝙚𝙜𝙪𝙡𝙖𝙩𝙞𝙤𝙣𝙨 + 𝙛𝙪𝙣𝙙𝙞𝙣𝙜 𝙜𝙖𝙥𝙨 = 𝙨𝙡𝙤𝙬𝙚𝙧 𝙞𝙣𝙣𝙤𝙫𝙖𝙩𝙞𝙤𝙣 But here’s the good news — The EU’s new 𝗕𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆 aims to change that with initiatives like: •  𝗘𝗨 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗔𝗰𝘁 ➡️ to strengthen Europe’s biotech competitiveness •  𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆 ➡️ aiming to make Europe “𝘵𝘩𝘦 𝘮𝘰𝘴𝘵 𝘢𝘵𝘵𝘳𝘢𝘤𝘵𝘪𝘷𝘦 𝘱𝘭𝘢𝘤𝘦 𝘧𝘰𝘳 𝘭𝘪𝘧𝘦 𝘴𝘤𝘪𝘦𝘯𝘤𝘦𝘴 𝘣𝘺 𝟤𝟢𝟥𝟢." 🚀 The real challenge now is to 𝘁𝘂𝗿𝗻 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝗶𝗲𝘀 𝗶𝗻𝘁𝗼 𝗱𝗲𝗹𝗶𝘃𝗲𝗿𝗶𝗲𝘀 — making innovation actually 𝘳𝘦𝘢𝘤𝘩 the people who 𝘯𝘦𝘦𝘥 it ⚕️ 👉 Your turn 𝘞𝘩𝘢𝘵 𝘴𝘩𝘰𝘶𝘭𝘥 𝘣𝘦 𝘌𝘶𝘳𝘰𝘱𝘦’𝘴 𝘵𝘰𝘱 𝘱𝘳𝘪𝘰𝘳𝘪𝘵𝘺 𝘵𝘰 𝘴𝘵𝘳𝘦𝘯𝘨𝘵𝘩𝘦𝘯 𝘣𝘪𝘰𝘱𝘩𝘢𝘳𝘮𝘢 𝘪𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘰𝘯 𝘣𝘺 𝟤𝟢𝟥𝟢? (Reply in the comments ⬇️) 1️⃣ Simplify regulations 2️⃣ Boost private funding 3️⃣ Speed up market access 📖 𝙁𝙪𝙡𝙡 𝙖𝙧𝙩𝙞𝙘𝙡𝙚: https://lnkd.in/eSQBumUR #LifeSciences #Biotechnology #EuropeBiotech #BiopharmaStrategy #PatientAccess #BiotechAct #RegulatoryChallenges

"China’s emergence as a biopharma powerhouse has become a hot topic in the industry. "Observers point to growing numbers of biotech startups, a surge in drug approvals, and major licensing deals flowing westward from China. This prompts worries that America could lose its long-held lead in biopharma innovation. "Before panicking, though, it’s important to step back and examine the root cause of China’s new prominence. There’s no magic to China’s biopharma boom; rather, it is the predictable result of its well-known ability to take commoditized business activities and scale them up. "The path forward for continuing U.S. leadership becomes much clearer with the underlying drivers properly understood." —Brian Finrow, Lumen Bioscience Read more ➡️ https://lnkd.in/eeiRSQ-Z #clinicaltrials #clinicalresearch

Building Effective Collaborations in Israel’s Biotech Landscape: CROs, Startups, and Pharma. Effective partnerships between CROs, biotech startups, and pharmaceutical companies are driving innovation across Israel’s life sciences sector. Recent success stories highlight several best practices: -Establish clear communication channels and milestones from day one. -Recognize and respect each partner’s unique strengths such as technical, regulatory, or market access. -Bridge cultural gaps with transparency, agility, and a willingness to learn from each other. -Focus on rapid iteration: pilot, evaluate, and scale what works. -Celebrate shared successes and always keep the end patient in mind. With Israel’s world-class talent and entrepreneurial spirit, fostering collaboration is key to advancing healthcare and shaping the future of global drug discovery. #Biotech #Collaboration #Innovation #CRO #Pharma #Israel

European biotech back on stage After two challenging years marked by rising interest rates and frozen capital markets, European biotech is back in the spotlight. The catalyst? Late-stage clinical success. Read more: https://lnkd.in/e5QVu-Nq

🚀 𝐓𝐚𝐧𝐝𝐞𝐦𝐀𝐈 𝐑𝐚𝐢𝐬𝐞𝐬 $𝟐𝟐𝐌 𝐭𝐨 𝐀𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐞 𝐀𝐈 𝐃𝐫𝐮𝐠 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐁𝐢𝐠 𝐦𝐨𝐦𝐞𝐧𝐭𝐮𝐦 𝐢𝐧 𝐩𝐡𝐚𝐫𝐦𝐚 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧! TandemAI has announced a $22 million Series A extension round focused on building its next-generation AI-enabled drug discovery platform. With this funding, the company plans to scale its computational and wet-lab capabilities, advance its pipeline across small molecules and peptides, and deepen partnerships with top global biopharma firms. 🧬💡 Read the full story 👉 https://lnkd.in/gKRmvjs8 📩 Want to share your insight or story? Drop us a line at → https://lnkd.in/gAkjVzEK #AIinPharma #DrugDiscovery #LifeSciencesInnovation #BiotechFunding #HealthTech

China is fast becoming a global powerhouse for drug innovation - with more CGT trials, including CAR-T trials taking place more than anywhere else. Explore the factors driving growth, and gain insights from China-based biotechs and pharma leaders on the keys to global success, and challenges ahead: https://vist.ly/4c6fv In partnership with ICON plc

Lonza’s Steady Course Toward Focus and Scale In its Q3 2025 update, Lonza didn’t release new numbers but it released a signal. “We are confirming our 2025 outlook of 20–21% growth and a 30–31% margin. Contracting is strong, and Vacaville is tracking exactly to plan.” Philippe Deecke, CFO That’s the message of a CDMO that has crossed the line from recovery to renewed conviction. What stands out: ·      Biologics momentum: Large-scale mammalian assets (including Vacaville) are humming. Lonza is showing that scale and flexibility can co-exist; a key differentiator in biologics manufacturing today. ·      Chemistry resilience: Advanced Synthesis (small molecules, HPAPIs, bioconjugates) keeps delivering. While others chase buzzwords, Lonza builds capacity and books multi-year deals. ·      Focus sharpening: The CHI (Capsules & Health Ingredients) carve-out moves closer. Divesting it will complete Lonza’s transformation into a pure-play CDMO. ·      U.S. footprint: Vacaville and Portsmouth expansions position Lonza squarely within the “reshoring narrative.” The U.S. wants domestic capacity and Lonza already has it. Behind the cautious Swiss tone lies a strategic truth: Lonza is evolving from a manufacturer of assets to a platform of trust for global Pharma. The next phase will be about resilience, integration, and value orchestration across biologics, HPAPIs, and modalities. Strategy isn’t about being loud. It’s about being predictable to yourself and unpredictable to others. Lonza seems to have rediscovered that balance. 🔔 Follow for insights ♻️ Share if you find it interesting   #lonza #strategy #cdmo

European biotech back on stage After two challenging years marked by rising interest rates and frozen capital markets, European biotech is back in the spotlight. The catalyst? Late-stage clinical success. Read more: https://lnkd.in/eCNxdh97

The golden goose in biologics isn’t capacity. It’s collaboration. Protein-based biologics can look perfect on paper but behave unpredictably once they move from lab to manufacturing. When that happens, it’s not just the molecule that’s tested. It’s the partnership. Here’s what separates smooth programs from stalled ones: • SMEs are involved early and stay engaged throughout execution. • CDMOs encourage open dialogue instead of one-way updates. • Tech transfer becomes a shared process, not a handoff. • Every team treats stability and formulation as living priorities, not checkboxes. In my latest article, “The Golden Goose of Biologics: Collaboration with Your CDMO,” I share why consulting your subject matter experts at every step is non-negotiable and how collaborative CDMOs turn complexity into momentum. I’m Sarah Sink, Your Pharma Girl. If your team is preparing to scale up or evaluating potential partners, check out my guide How to Compare CDMO Quotes: 10 Factors Beyond Cost to help you identify which CDMOs truly foster partnership and alignment. Article link is in the first comment. #CDMO #businessdevelopment #biotech #yourpharmagirl

Biotech’s deal flow isn’t dead. It’s just getting smarter. 🧠 Roche just reported 7% year-over-year growth, bringing in CHF 45.9B ($57.5B) over the first nine months of 2025. The pharma giant’s Q3 results were solid, but the real headline is how aggressive they’re getting with dealmaking again. In just a few months: 💰 $3.5B buyout of 89bio for its MASH candidate, pegozafermin 🧬 $2B+ Genentech–Orionis protein degrader partnership 🤖 $1B+ Chugai–Gero AI drug discovery deal On the earnings call, Roche CEO Thomas Schinecker made it clear: “We’re not done with BD.” The timing says a lot. After two years of tight capital, investors are finally stepping back into biotech, just more selectively. Late-stage assets, validated science, and AI-driven efficiency are pulling funding, while early-stage moonshots are still fighting for scraps. Roche’s deal spree signals a new phase for the industry: capital’s back, but confidence has conditions. Read the full story here: https://lnkd.in/eAz6cTEX 📩 Get more insights like this from our weekly newsletter. Sign up here: https://lnkd.in/e92yh9kw #biotech #biotechnews #biotechfunding #venturecapital #lifesciences #pharma #roche #biotechdeals #biotechvc